{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:13:20Z","timestamp":1793196800377,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jaad.2024.03.025","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T18:29:09Z","timestamp":1711650549000},"page":"91-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study"],"prefix":"10.1016","volume":"91","author":[{"given":"Kurt","family":"Gebauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Spelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Bagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar","family":"Nishandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Crane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Kopeloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudgal","family":"Kothekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siu-Long","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard L.","family":"Sofen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2024.03.025_bib1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bjd.17403","article-title":"Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients","volume":"181","author":"Augustin","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2024.03.025_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12895-020-00099-7","article-title":"Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort","volume":"20","author":"Egeberg","year":"2020","journal-title":"BMC Dermatol"},{"key":"10.1016\/j.jaad.2024.03.025_bib3","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/ced.12805","article-title":"Prevalence of psoriasis phenotypes among men and women in the USA","volume":"41","author":"Merola","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2024.03.025_bib4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2340\/00015555-1731","article-title":"Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex","volume":"94","author":"Sampogna","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2024.03.025_bib5","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jaad.2008.11.890","article-title":"Treatment of severe scalp psoriasis: from the medical board of the National Psoriasis Foundation","volume":"60","author":"Chan","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2024.03.025_bib6","first-page":"33","article-title":"Management of scalp psoriasis: current perspectives","volume":"6","author":"Blakely","year":"2016","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.jaad.2024.03.025_bib7","doi-asserted-by":"crossref","first-page":"84","DOI":"10.51866\/oa.146","article-title":"Scalp psoriasis and dermatology life quality index: a retrospective study based on 12-year data from the Malaysian psoriasis registry","volume":"17","author":"Leong","year":"2022","journal-title":"Malays Fam Physician"},{"key":"10.1016\/j.jaad.2024.03.025_bib8","first-page":"309","article-title":"Quality of life in patients with scalp psoriasis","volume":"150","author":"Zampieron","year":"2015","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.jaad.2024.03.025_bib9","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2024.03.025_bib10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","article-title":"Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council","volume":"82","author":"Strober","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2024.03.025_bib11","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2024.03.025_bib12","series-title":"ILUMYA\u00ae (tildrakizumab-asmn [prescribing information]","year":"2023"},{"key":"10.1016\/j.jaad.2024.03.025_bib13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/jdv.18572","article-title":"Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: results from the non-interventional, prospective, multicentre study TILOT","volume":"37","author":"Tsianakas","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2024.03.025_bib14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/09546634.2013.865009","article-title":"The 5-point Investigator's Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials","volume":"26","author":"Langley","year":"2015","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2024.03.025_bib15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1477-7525-7-62","article-title":"The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups","volume":"7","author":"Globe","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jaad.2024.03.025_bib16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jaad.2011.07.034","article-title":"Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept","volume":"67","author":"Bagel","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2024.03.025_bib17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaad.2017.05.033","article-title":"The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study","volume":"77","author":"Bagel","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2024.03.025_bib18","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamadermatol.2018.0793","article-title":"Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials","volume":"154","author":"Foley","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2024.03.025_bib19","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1080\/09546634.2016.1249820","article-title":"Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)","volume":"28","author":"Reich","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2024.03.025_bib20","doi-asserted-by":"crossref","unstructured":"Papp K, Lebwohl M, Gottlieb A et\u00a0al. Bimekizumab for the treatment of moderate to severe plaque psoriasis with scalp, nail and palmoplantar involvement through 52 weeks: post-hoc analysis from the BE VIVID phase 3 trial. Poster presented at the European Academy of Dermatology & Venereology (EADV) 29th Congress; October 29-31, 2020; Virtual.","DOI":"10.25251\/skin.5.supp.18"},{"key":"10.1016\/j.jaad.2024.03.025_bib21","unstructured":"Reich K, Merola JF, Elewski B et\u00a0al. Bimekizumab for the treatment of moderate to severe psoriasis of the scalp: post-hoc analysis from the BE SURE phase 3 trial. Poster presented at the European Academy of Dermatology & Venereology (EADV) 28th Congress; October 13-14, 2019; Madrid, Spain."},{"key":"10.1016\/j.jaad.2024.03.025_bib22","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2024.03.025_bib23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2024.03.025_bib24","unstructured":"Elewski B, Rich P, Crowley J et\u00a0al. Risankizumab profile in nail, scalp, and palmoplantar psoriasis: efficacy and safety at 52 weeks in an integrated analysis of patients with moderate-to-severe plaque psoriasis. Poster presented at the 24th World Congress of Dermatology; June 10-15, 2019; Milan, Italy."},{"key":"10.1016\/j.jaad.2024.03.025_bib25","article-title":"Improvement in scalp psoriasis with brodalumab in a randomized placebo-controlled phase 3 study (AMAGINE-1)","volume":"76","author":"Yamauchi","year":"2017","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222400536X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222400536X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T06:37:45Z","timestamp":1722321465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096222400536X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S019096222400536X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2024.03.025","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2024.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}